They're not reinvesting in new drugs. The evergreening is also really concerning. They can re-patent drugs on a constant basis because they tweak the formula very lightly.
Something else that you talked about are NAFTA cases, which again speak to the ISDS provisions and our concerns around that. When you ask most Canadians about the TPP, this is one of the provisions they talk about. They are concerned because we're the most sued country under these provisions. You mentioned one case in New Brunswick, public auto insurance. I wonder if you could expand on that a little bit and tell us what ended up happening there.